MNPR Stock Analysis: Buy, Sell, or Hold?
MNPR - Monopar Therapeutics Inc. Common Stock
$107.72
-3.16 (-2.85%)
▼
5d:
-4.71%
30d:
+1.91%
90d:
+71.86%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 11, 2026
0d
Get Alerted When MNPR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: MNPR shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: MNPR shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: MNPR is currently trading at $107.72, which is considered oversold relative to its 30-day fair value range of $108.36 to $117.78.
Technical Outlook: Technically, MNPR is in a strong uptrend. The price is currently testing key support at $105.42. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: MNPR scores 16/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $126.31 (+17.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, MNPR is in a strong uptrend. The price is currently testing key support at $105.42. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: MNPR scores 16/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $126.31 (+17.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$108.36 -
$117.78
Company Quality Score
47/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
55.3%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (16/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($126.31)
- WARNING: Composite score 47/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$108.36 -
$117.78
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$105.42
Resistance Level
$124.27
Current Trend
Strong Uptrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-54.40
Wall Street Target
$126.31
(+17.3%)
Share & Embed Analysis
Last updated: August 24, 2026 1:48 AM ET
Data refreshes hourly during market hours. Next update: 2:48 AM
Data refreshes hourly during market hours. Next update: 2:48 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MNPR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$24 | 33 SELL |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$840 | 34 SELL |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$281 | 55 HOLD |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$29 | 49 HOLD |
|
DYN
Dyne Therapeutics Inc |
STRONG BUY
14 analysts |
$39 | 52 HOLD |
